Cordis Launches SELUTION SLR™ PTA Drug-Eluting Balloon in Japan
Cordis has launched the SELUTION SLR™ PTA Drug-Eluting Balloon in Japan, which is designed to deliver sirolimus to reduce restenosis and restore vessel function. Clinical trial results show promising outcomes in a complex patient population.
TOKYO–(BUSINESS WIRE)– #Cordis–Cordis, a global leader in interventional cardiovascular technologies, today announces the launch and availability of the SELUTION SLR™ PTA Drug-Eluting Balloon (DEB)1 for use in Japan. SELUTION SLR™ DEB is designed to deliver sirolimus in a controlled, sustained manner to reduce restenosis and restore vessel function. The SELUTION SFA Japan clinical trial results demonstrate durable clinical outcomes in a complex patient population, including 81.5% primary patency and 9